Lymphangioleiomyomatosis · Claude Code

1. Disease Information

Overview. Lymphangioleiomyomatosis (LAM) is a rare, slowly progressive, low-grade neoplastic (metastasizing) disease that almost exclusively affects women, typically in their reproductive years. It is characterized by diffuse cystic destruction of the lung parenchyma, abnormal proliferation of immature smooth-muscle-like "LAM cells" along lymphatics, airways, and blood vessels, and a strong association with renal angiomyolipomas (AMLs) and chylous (lymphatic) effusions. It is now understood as a member of the PEComa family (perivascular epithelioid cell tumors) and behaves like a low-grade, hormonally responsive, metastasizing neoplasm — a "benign metastasizing" tumor of the lung ("a wolf in sheep's clothing," JCI 2012, https://www.jci.org/articles/view/58709).

Two clinical contexts exist: - Sporadic LAM (S-LAM): arises from somatic TSC2 mutations; not inherited. - TSC-LAM: occurs in patients with the germline disorder Tuberous Sclerosis Complex (TSC); affects up to 30–40% of adult women with TSC (and is detectable on CT in a substantial fraction of men with TSC, though usually asymptomatic).

Key identifiers: - MONDO: MONDO:0011705 (https://monarchinitiative.org/MONDO:0011705) - OMIM: #606690 — "LYMPHANGIOLEIOMYOMATOSIS; LAM" (https://omim.org/entry/606690) - Orphanet: ORPHA:538 - MedGen: C0751674 - ICD-10: J84.81 (Lymphangioleiomyomatosis); ICD-11: CB04.1 / under interstitial lung diseases (also coded among rare cystic lung diseases) - MeSH: D018192 "Lymphangioleiomyomatosis" - NCIT: C3725 (Lymphangioleiomyomatosis) - Related upstream gene disorders: TSC1 (OMIM 605284), TSC2 (OMIM 191092); Tuberous Sclerosis (OMIM 191100/613254)

Synonyms / alternative names: Lymphangiomyomatosis; LAM; pulmonary lymphangioleiomyomatosis; lymphangiomyoma; sporadic lymphangioleiomyomatosis (S-LAM); tuberous-sclerosis–associated LAM (TSC-LAM). (Note: "lymphangiomyomatosis" is the legacy OMIM/ClinVar spelling.)

Data derivation: Disease-level resource (aggregated). LAM knowledge derives from disease-level registries and natural-history cohorts (NHLBI LAM Registry, the LAM Foundation registry, Japanese national insurance-claims database, ERS/ATS guideline cohorts) rather than single-patient EHR records.

Sources: OMIM 606690 (https://omim.org/entry/606690); Monarch MONDO:0011705; StatPearls (https://www.ncbi.nlm.nih.gov/books/NBK534231/); clinical review, Breathe 2020 (https://publications.ersnet.org/content/breathe/16/2/200007); PMC7714539 (https://pmc.ncbi.nlm.nih.gov/articles/PMC7714539/).

2. Etiology

Primary cause — genetic/mechanistic. LAM is caused by biallelic inactivation of the tumor-suppressor genes TSC1 (9q34, encoding hamartin) or, far more commonly, TSC2 (16p13.3, encoding tuberin). Loss of the TSC1–TSC2–TBC1D7 complex (a GTPase-activating complex for the small GTPase RHEB) leads to constitutive activation of mTOR complex 1 (mTORC1), driving inappropriate cell growth, proliferation, survival, and lymphangiogenesis.

In sporadic LAM, LAM cells carry somatic TSC2 mutations plus loss of heterozygosity (LOH) at the second allele (two-hit Knudson mechanism). LOH at chromosome 16p13 (the TSC2 locus) is detectable in pulmonary LAM cells, lymph-node LAM cells, and angiomyolipoma cells (Carsillo, Astrinidis & Henske, PNAS 2000 — PMID:10737804, verify; "Angiomyolipoma cells and pulmonary LAM cells from sporadic LAM patients contain inactivating mutations in the TSC2 gene that arose somatically").
In TSC-LAM, one TSC1/TSC2 allele is mutated in the germline; a somatic second hit occurs in the LAM cell.
A metastatic ("benign metastasis") model is strongly supported: identical TSC2 mutations are found across spatially separate lesions, and recurrent LAM in transplanted donor lungs has been shown by genetic analysis to derive from recipient cells (Karbowniczek et al., Am J Respir Crit Care Med 2003, https://www.atsjournals.org/doi/full/10.1164/rccm.200208-969OC — "cells in recurrent LAM lesions in donor lungs … derive from the recipient rather than from the allografts").

Risk factors: - Female sex — overwhelmingly the dominant risk factor; near-exclusive female predominance. - Reproductive-age / hormonal status — onset and progression cluster in the premenopausal period; estrogen is a key disease driver (see §5). - Germline TSC1/TSC2 mutation (Tuberous Sclerosis Complex) — strongest genetic risk factor; TSC raises LAM risk dramatically. - Family history — only relevant via TSC (sporadic LAM is not heritable). - Pregnancy and exogenous estrogen — associated with accelerated progression and pneumothorax risk in observational data; estrogen-containing contraceptives are generally cautioned against.

Protective factors: - Menopause / estrogen withdrawal is associated with slower decline; lung-function decline tends to attenuate after menopause. - No validated genetic protective variants are established. Anti-estrogen states (oophorectomy historically attempted) were proposed as protective but lack robust trial support.

Gene–environment interaction. The central interaction is TSC2 loss × estrogen signaling: tuberin-deficient cells are hormonally responsive; estrogen promotes LAM-cell survival (via inhibition of anoikis), migration, MEK–ERK signaling, and pulmonary metastasis in preclinical models (see §6 and §15). This explains why a constitutive genetic lesion produces a sex- and reproductive-stage-restricted disease.

Sources: OMIM 606690; PMC7714539; AJP Cell Physiol 2022 (https://journals.physiology.org/doi/full/10.1152/ajpcell.00202.2022); Karbowniczek 2003.

3. Phenotypes

LAM is a multisystem disease dominated by pulmonary, lymphatic, and renal manifestations. Approximate frequencies below are drawn from registry/cohort literature (NHLBI LAM Registry; ATS/JRS guideline; Orphanet).

Table (click to expand)

Phenotype	Type	Suggested HPO	Approx. frequency	Notes / characteristics
Progressive exertional dyspnea	Symptom	HP:0002875 (Exertional dyspnea) / HP:0002094 (Dyspnea)	Very frequent (~70–80%)	Adult-onset; progressive; the dominant presenting symptom
Spontaneous pneumothorax	Clinical sign/event	HP:0002107 (Pneumothorax)	~50–70% over disease course; recurrent	Often the presenting event; recurrence rate very high (~70% without pleurodesis)
Diffuse pulmonary cysts (thin-walled, bilateral)	Imaging/physical	HP:0009789 (Pulmonary cyst) / HP:0032967 (Cystic lung disease, verify)	~Universal (defining)	Bilateral, diffuse, round, thin-walled; uniform distribution
Chylothorax	Clinical sign	HP:0030758 (Chylothorax, verify) / HP:0010310 (Chylous pleural effusion)	~10–30%	Due to lymphatic obstruction; can be recurrent/large
Chylous ascites / chyluria	Clinical sign	HP:0030245 (Chylous ascites, verify)	Less common	Lymphatic involvement of abdomen
Renal angiomyolipoma	Tumor/sign	HP:0006772 (Renal angiomyolipoma, verify) / HP:0009592 (Angiomyolipoma)	~30–50% (S-LAM); up to ~80–90% (TSC-LAM)	Risk of hemorrhage if >4 cm or aneurysm >5 mm
Lymphangioleiomyoma (cystic lymphatic mass)	Tumor/sign	HP:0100763 (Lymphangioma, verify)	~16–40%	Retroperitoneal/pelvic; may fluctuate in size diurnally
Hemoptysis	Symptom	HP:0002105 (Hemoptysis)	Occasional	Usually mild
Cough	Symptom	HP:0012735 (Cough)	Frequent
Airflow obstruction (↓FEV₁, ↓FEV₁/FVC)	Lab/PFT	HP:0006510 (Chronic pulmonary obstruction, verify) / HP:0030877 (Reduced FEV1, verify)	Frequent, progressive	Obstructive pattern; reduced DLCO is common and often early
Reduced DLCO	Lab/PFT	HP:0045051 (Abnormal DLCO, verify)	Frequent	Sensitive early marker
Chronic respiratory failure / hypoxemia	Sign	HP:0002878 (Respiratory failure) / HP:0012418 (Hypoxemia)	Advanced disease	End-stage
Elevated serum VEGF-D	Lab abnormality	(no specific HP)	Frequent (diagnostic)	>800 pg/mL is diagnostic in correct context (see §10)
Fatigue / reduced exercise capacity	Symptom	HP:0012378 (Fatigue)	Frequent	Reduced 6-minute-walk distance

Quality-of-life impact: Progressive dyspnea, oxygen dependence, recurrent pneumothorax/effusions, and the emotional burden of a rare progressive disease substantially reduce HRQoL. Lung-function decline and 6-minute-walk distance correlate with QoL and mortality (Determinants of Progression and Mortality, Chest 2023, https://www.sciencedirect.com/science/article/pii/S0012369223002726).

Sources: ATS/JRS guideline PMID:27628078; Orphanet ORPHA:538; Breathe 2020 review; StatPearls.

4. Genetic / Molecular Information

Causal genes: - TSC2 — 16p13.3, encodes tuberin; HGNC:12363; OMIM 191092. The dominant gene in sporadic LAM. - TSC1 — 9q34, encodes hamartin; HGNC:12362; OMIM 605284. Rarely implicated in sporadic LAM; more in TSC.

The TSC1–TSC2–TBC1D7 complex is the GAP for RHEB-GTP; loss → RHEB-GTP accumulation → mTORC1 hyperactivation.

Pathogenic variants: - Variant types: the full spectrum of loss-of-function lesions — nonsense, frameshift (indels), splice-site, missense, large deletions/structural rearrangements, plus second-hit LOH at 16p13. ClinVar examples include TSC2 c.501G>A (p.Trp167Ter) nonsense and TSC2 c.5160+4A>C splice variants annotated to "Lymphangiomyomatosis" (https://www.ncbi.nlm.nih.gov/clinvar/RCV001195824/, RCV001196213/). - Classification: Per ACMG/AMP, truncating LoF variants in TSC2 are typically Pathogenic/Likely Pathogenic; many missense are VUS. - Somatic vs germline: Somatic in S-LAM (with LOH); germline + somatic second hit in TSC-LAM. Somatic mosaicism for TSC2 has been documented even in isolated/"sporadic" LAM, including rare male cases (PMC10849871; PMC7340110 "Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis"). - Functional consequence: Loss of function of tuberin (a tumor suppressor) → mTORC1 gain of activity (a "two-hit," recessive-at-cellular-level mechanism). - Allele frequency: Causal somatic mutations are private/not in population databases; germline TSC variants in gnomAD are exceedingly rare.

Modifier genes / interacting loci: Estrogen-receptor-α (ESR1) signaling, Wnt/β-catenin, and downstream effectors modulate phenotype; no formal Mendelian modifier gene is established. mTORC1 hyperactivation cross-talks with ERα, Wnt, FGF, SHH, and TGFβ signaling to produce the cystic phenotype (PMC7714539; AJP Cell Physiol 2022).

Epigenetics: A 3D drug-screen study implicated HDAC dependency in mTORC1-driven LAM, nominating HDAC inhibitors (bioRxiv 2021, https://www.biorxiv.org/content/10.1101/2021.07.03.451004). Epigenetic regulation is an emerging but not yet clinically actionable area.

Chromosomal abnormalities: No recurrent karyotypic aberration beyond locus-specific LOH at 16p13 (TSC2) detected in microdissected LAM cells.

Sources: OMIM 606690/191092; ClinVar TSC2 records; PMC10849871; PMC7340110; Carsillo/Henske PNAS 2000 (PMID:10737804, verify).

5. Environmental Information

Environmental/occupational toxins: No established environmental cause. LAM is genetically driven.
Hormonal "environment" (key modifiable factor): Estrogen (endogenous and exogenous). Pregnancy, estrogen-containing oral contraceptives, and hormone-replacement therapy are associated with disease acceleration/complications; clinicians generally advise avoiding supplemental estrogen.
Lifestyle: Smoking is not causal but worsens obstructive lung disease and should be avoided. Air travel carries a modest pneumothorax risk in patients with cysts (PMC6293523, "Air travel and incidence of pneumothorax in lymphangioleiomyomatosis").
Infectious agents: None — LAM is not infectious.

Sources: PMC6293523; ATS/JRS guideline; Endocrinology minireview (https://academic.oup.com/endo/article/157/9/3374/2422360).

6. Mechanism / Pathophysiology

Central causal chain (upstream → downstream):

Biallelic TSC2 (or TSC1) loss in a LAM cell → loss of TSC1–TSC2–TBC1D7 GAP activity.
RHEB-GTP accumulation → constitutive mTORC1 activation ("mTORC1, a key controller of cell growth and metabolism, is inappropriately activated"; PMC7714539).
mTORC1 drives anabolic output chiefly via S6K1→ribosomal protein S6 and 4E-BP1→eIF4E, boosting cap-dependent mRNA translation, ribosome biogenesis, lipid/nucleotide synthesis, and HIF/VEGF programs.
VEGF-D (and VEGF-C) overproduction → lymphangiogenesis and lymphatic spread; VEGF-D is the serum biomarker correlate.
Estrogen (ERα) synergy: mTORC1 activation synergizes with ERα; estrogen promotes survival (anoikis resistance), migration, MEK1/2–ERK1/2 signaling, and pulmonary metastasis of TSC2-deficient cells (PMC4992946; Discover Oncology 2014).
Wnt/β-catenin, FGF, SHH, TGFβ up-regulation → the cystic remodeling phenotype (PMC7714539).
Matrix destruction: LAM cells and recruited cells produce matrix metalloproteinases (MMP-2, MMP-9) and cathepsin-K, degrading elastin/ECM → progressive airspace cyst formation and lung destruction (rationale for doxycycline as an anti-MMP agent — modest/uncertain benefit).
Lymphatic dissemination & "benign metastasis": LAM cells circulate, seed the lung, proliferate around lymphatics/airways/vessels → cysts, lymphatic obstruction (chylous effusions), and lymphangioleiomyomas.

Cellular processes: dysregulated cell growth/proliferation, evasion of anoikis/apoptosis, autophagy modulation (mTORC1 suppresses autophagy — basis for the sirolimus + autophagy-inhibition trials, PMC6026235), metabolic reprogramming, lymphangiogenesis, ECM proteolysis. The proapoptotic protein Bim mediates anoikis that estrogen overcomes (PMC5111508). Estradiol also augments tumor-induced neutrophil production to promote metastasis (PMC10164661).

Cell of origin: Uncertain but converging on a uterine/neural-crest-related smooth-muscle lineage. Uterine-specific Tsc2 deletion in mice produces myometrial tumors that spontaneously metastasize to lung (PMC3753421; "Identification of the lymphangioleiomyomatosis cell and its uterine origin," bioRxiv). LAM cells co-express melanocytic (HMB-45, gp100, Melan-A, MITF) and smooth-muscle (SMA, desmin) markers, plus ERα/PgR, consistent with a neural-crest–related, PEComa lineage (Frontiers 2014, PMC4243694).

Suggested ontology terms (mechanism): - GO: GO:0032008 (positive regulation of TOR signaling), GO:0031929 (TOR signaling), GO:0001525 (angiogenesis), GO:0001946 (lymphangiogenesis), GO:0030198 (extracellular matrix organization), GO:0043066 (negative regulation of apoptotic process), GO:0006914 (autophagy). - CL: CL:0000192 (smooth muscle cell), CL:0000669 (pericyte, verify), CL:0000148 (melanocyte, partial-marker analogy), CL:0002138 (endothelial cell of lymphatic vessel). - CHEBI: CHEBI:9168 (sirolimus), CHEBI:16469 (17β-estradiol), CHEBI:50845 (doxycycline), CHEBI:68481 (everolimus, verify), CHEBI:42261 (rapamycin synonym).

Sources: PMC7714539; PMC10523142; AJP Cell Physiol 2022; PMC4992946; PMC5111508; PMC10164661; PMC3753421; PMC4243694; PMC6026235.

7. Anatomical Structures Affected

Primary organ: Lung (UBERON:0002048) — diffuse bilateral cystic destruction of parenchyma; involvement of bronchioles, pulmonary vessels, and lymphatics.
Lymphatic system (UBERON:0006558 lymphatic vessel; thoracic duct UBERON:0001473) — lymphangioleiomyomas, chylous effusions, axial lymphatic involvement (mediastinum, retroperitoneum, pelvis).
Kidney (UBERON:0002113) — angiomyolipomas (fat-/muscle-/vessel-containing benign tumors).
Pleura (UBERON:0000977) — pneumothorax, chylothorax.
Uterus / myometrium (UBERON:0001295) — proposed origin; myometrial smooth-muscle involvement.
Mediastinum / retroperitoneum / abdomen — nodal masses, chylous ascites.

Tissue/cell level: - Affected tissue: smooth muscle / mesenchymal connective tissue, lymphatic and pulmonary epithelium (secondary). - Target cell: the LAM cell — a perivascular epithelioid cell with spindle (smooth-muscle-like, SMA/desmin+) and epithelioid (HMB-45/Melan-A+) morphologies; ERα/PgR positive. CL: CL:0000192 (smooth muscle cell); melanocytic differentiation (CL:0000148 melanocyte) as marker analogy.

Subcellular: mTORC1 signaling node at the lysosomal membrane (GO:0005765); cytoplasmic translational machinery (ribosome, GO:0005840); nucleus (ERα transcriptional program, GO:0005634).

Localization / laterality: Pulmonary disease is bilateral and diffuse/symmetric; pneumothorax may be unilateral at presentation; angiomyolipomas often bilateral.

Sources: ATS/JRS guideline; StatPearls; Molecular Pathology of LAM/PEComa (https://meridian.allenpress.com/aplm/article/134/1/33/460876).

8. Temporal Development

Onset: Adult-onset; typical diagnosis in the third to fourth decade (premenopausal). TSC-LAM may be detected earlier via TSC surveillance. Congenital/pediatric onset is essentially not seen.
Onset pattern: Insidious (progressive dyspnea) or acute when presenting as spontaneous pneumothorax or chylothorax.
Progression: Chronic, generally slowly progressive but variable. Disease progression is operationally defined as a ≥10% absolute decline in FEV₁. Untreated, mean FEV₁ decline is on the order of ~75–120 mL/year (placebo arm of MILES showed FEV₁ slope ≈ −12 mL/month, i.e., ~−134 mL/yr in moderately impaired patients; PMID:21410393). Rate is faster in patients with higher baseline VEGF-D and worse histology score.
Course pattern: Progressive, occasionally punctuated by acute events (pneumothorax, effusion). Menopause tends to slow decline.
Disease stages: Early (preserved PFTs, incidental cysts) → intermediate (obstructive PFTs, symptomatic) → advanced/end-stage (respiratory failure, oxygen dependence, transplant candidacy).
Remission: No spontaneous remission; treatment-induced stabilization (not cure) with mTOR inhibitors. Disease typically resumes progression upon drug cessation (PMC10523142).
Critical intervention window: Initiate sirolimus at/early after a decline of FEV₁ (e.g., FEV₁ <70% predicted or rapid decline) to preserve function.

Sources: MILES PMID:21410393; Predicting Individualized Progression, Chest 2023 (PMC10258438); Natural History (PMC2883494); Long-term outcomes PMID:35717210.

9. Inheritance and Population

Epidemiology: - Prevalence (S-LAM): ~3–8 per million women; commonly cited ~1 in 400,000 adult women. Japanese national-database data (2019): prevalence ~28.7 per million women, incidence ~3 per million women-years (ScienceDirect, J Investig Med?/ ERJ Open?, https://www.sciencedirect.com/science/article/abs/pii/S2212534524000522). - Men: incidence <0.2/million-yr, prevalence ~0.8/million (essentially only in TSC). - TSC-LAM: cystic lung changes occur in ~30–40% of adult women with TSC (higher with age).

Inheritance pattern: - Sporadic LAM: NOT inherited (somatic two-hit, like a tumor). - TSC-LAM: Tuberous Sclerosis is autosomal dominant (TSC1/TSC2), with high spontaneous-mutation rate (~⅔ de novo); LAM then arises via somatic second hit. Penetrance of LAM within TSC is incomplete and sex-biased (clinically penetrant mainly in women). Variable expressivity is the rule. - Germline/somatic mosaicism: documented (relevant to rare apparent-sporadic and male cases). - Anticipation, founder effects, consanguinity, carrier frequency: Not applicable to sporadic LAM; standard TSC genetics apply to TSC-LAM.

Demographics: - Sex ratio: Overwhelmingly female (sporadic LAM essentially female-only; very rare male cases reported, usually with TSC or mosaicism). - Age: Predominantly reproductive-age women (20s–40s) at diagnosis. - Ethnic/geographic: No strong ethnic predilection; reported worldwide. Apparent regional differences largely reflect ascertainment.

Sources: Japan national database study (S2212534524000522); Orphanet ORPHA:538; Medscape (https://emedicine.medscape.com/article/299545-overview); StatPearls.

10. Diagnostics

Imaging (cornerstone): - HRCT chest: numerous, bilateral, diffuse, thin-walled round cysts with normal intervening parenchyma — characteristic and often diagnostic in the right clinical context (RadLex; ATS/JRS guideline). Abdominal CT/MRI for AMLs and lymphangioleiomyomas.

Biomarker: - Serum VEGF-D — the key non-invasive diagnostic test. ≥800 pg/mL in a woman with characteristic cystic HRCT is diagnostic of LAM (avoids biopsy); a cut-off ~645 pg/mL is sensitive, ~800 pg/mL is specific (PLOS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212776; Young et al., Respir Res 2012, PMID:22513045 — "combining ERS criteria and serum VEGF-D reduc[es] the need for lung biopsy"). VEGF-D also tracks treatment response (falls on sirolimus) and correlates with lymphatic involvement.

Other supportive tests: - PFTs: obstructive pattern (↓FEV₁, ↓FEV₁/FVC), reduced DLCO; air trapping. Used for staging and monitoring. - 6-minute walk test, pulse oximetry for functional staging. - Pleural fluid analysis: chylous (triglyceride-rich) effusion.

Histopathology / biopsy (when imaging+biomarker inconclusive): - Transbronchial lung biopsy (often diagnostic; 2017 ATS/JRS addendum supports it, PMC5694834) or surgical biopsy. - Microscopy: nodular/diffuse proliferation of spindle and epithelioid smooth-muscle-like cells around cysts, lymphatics, and vessels. - Immunohistochemistry: HMB-45 positive (~most sensitive melanocytic marker for LAM cells), SMA/desmin positive, ERα and PgR positive; Melan-A, MITF, cathepsin-K may be positive. (Molecular Pathology of LAM/PEComa, Allenpress 2010.)

Genetic testing: - Indicated to evaluate for TSC (germline TSC1/TSC2 panel/sequencing + deletion/duplication analysis) when TSC features are present or in younger/multifocal disease. Sporadic LAM is diagnosed clinically (HRCT + VEGF-D ± biopsy); somatic TSC2 testing of lesional tissue is research-oriented.

Diagnostic criteria: ATS/JRS 2016 and ERS 2010 criteria integrate characteristic HRCT + at least one of: AML, chylous effusion, lymphangioleiomyoma, TSC, or serum VEGF-D ≥800 pg/mL (or confirmatory biopsy).

Differential diagnosis: Birt-Hogg-Dubé syndrome (basilar cysts, FLCN), pulmonary Langerhans cell histiocytosis (smoking, upper-lobe nodules/cysts), emphysema/COPD, Sjögren-associated LIP/cystic disease, amyloidosis, light-chain deposition disease, follicular bronchiolitis. VEGF-D and cyst morphology distinguish LAM.

Suggested MAXO/diagnostic terms: MAXO:0000455 (chest CT, verify); biomarker assay; histopathology examination (MAXO:0000823, verify).

Sources: ATS/JRS 2016 (PMID:27628078); 2017 addendum (PMC5694834); Summary for Clinicians (PMC5566288); VEGF-D PLOS One 2019; Young 2012 (PMID:22513045).

11. Outcome / Prognosis

Survival: Generally favorable with modern care. Recent cohorts report 5-year ~90–93% and 10-year ~85–91% survival (Long-term outcomes, Respir Res 2022, PMID:35717210). Historically (pre-sirolimus, transplant-era cohorts) median survival/transplant-free survival was lower; outcomes have improved markedly.
Prognostic factors (independent predictors of mortality): older age, lower FEV₁ and DLCO, shorter 6-minute-walk distance, higher LAM histology score (LHS-3 worst: ~52% survival at 156 months), and higher baseline/rising VEGF-D (Determinants of Progression and Mortality, Chest 2023).
Disease course / morbidity: recurrent pneumothorax, chylous effusions, AML hemorrhage, progressive exertional limitation, oxygen dependence; significant QoL burden.
Recovery potential: No cure; mTOR inhibitors stabilize but do not reverse lung destruction and must be continued; benefit wanes on discontinuation.
End-stage: Respiratory failure → lung transplantation (good outcomes; FEV₁ ~48–49% predicted at 6–12 months post-transplant per NEJM 1996 series). Recurrence of LAM in the allograft can occur (recipient-derived), reinforcing the metastatic model — but is usually clinically indolent.
Prognostic biomarker: serum VEGF-D (diagnostic + monitoring).

Sources: PMID:35717210; Chest 2023 (S0012369223002726); MILES PMID:21410393; Lung Transplantation NEJM 1996 (https://www.nejm.org/doi/full/10.1056/NEJM199610243351704).

12. Treatment

Pharmacotherapy (disease-modifying): - Sirolimus (rapamycin) — allosteric mTORC1 inhibitor; first-line, evidence-based therapy. The pivotal MILES trial (RCT, n=89, NEJM 2011, PMID:21410393) showed sirolimus stabilized FEV₁ (slope +1 vs −12 mL/month placebo), reduced VEGF-D, and improved symptoms/QoL — "sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life." Benefit reverses on cessation. Indicated for FEV₁ <70% predicted, rapid decline, or problematic chylous effusions/AML. MAXO: pharmacotherapy; CHEBI:9168 (sirolimus); therapeutic_modality: SMALL_MOLECULE. - Everolimus — second mTORC1 inhibitor; used especially for renal angiomyolipoma (EXIST-2 trial established AML shrinkage with everolimus; FDA-approved for TSC-associated AML) and as a sirolimus alternative. CHEBI:68481 (verify). - Doxycycline — anti-MMP rationale; trials (e.g., the UK doxycycline trial) showed no clear lung-function benefit; not routinely recommended (ATS/JRS: do not use to improve lung function). - Hormonal manipulation (anti-estrogen, progesterone, GnRH analogs, oophorectomy): historically used; not recommended by ATS/JRS due to lack of efficacy and harms; avoid exogenous estrogen.

Pharmacogenomics: No validated pharmacogenomic dosing for sirolimus in LAM beyond therapeutic drug monitoring (target trough ~5–15 ng/mL, often lower in LAM ~5–10).

Experimental / advanced therapeutics (clinical trials): - Sirolimus + autophagy inhibition (hydroxychloroquine) — SAIL phase I (PMC6026235, NCT01687179). - Resveratrol + sirolimus — RESET trial (NCT03253913). - Aromatase inhibitors (letrozole) — TRAIL trial in postmenopausal LAM. - HDAC inhibitors — preclinical lead (bioRxiv 2021). - Other mTOR/autophagy/anti-estrogen combinations and inhaled sirolimus are under study.

Supportive / interventional: - Pleurodesis (chemical or surgical) for recurrent pneumothorax/chylothorax; pleurodesis is preferred even after a first pneumothorax given high recurrence (ATS/JRS). - Embolization or nephron-sparing surgery for large/bleeding renal AML (>4 cm or aneurysm >5 mm). - Supplemental oxygen, pulmonary rehabilitation, bronchodilators (some have reversible obstruction), vaccinations, dietary management of chylous effusions (low-fat/MCT diet). - Lung transplantation for end-stage disease (MAXO:0010039 organ transplantation).

Treatment outcomes: Sirolimus stabilizes FEV₁ and reduces VEGF-D in the majority; common adverse events: mucositis/stomatitis, acne-like rash, hyperlipidemia, edema, cytopenias, infections, diarrhea. Real-world data confirm durable stabilization with continued therapy (PMC10713282, "mTOR inhibitors in real world").

Suggested MAXO terms: MAXO:0000058 (pharmacotherapy/therapeutic, verify; or NCIT:C15986 Pharmacotherapy), MAXO:0010039 (organ transplantation), MAXO:0000950 (supportive care), MAXO:0000004/NCIT:C15329 (surgical procedure for pleurodesis/AML), MAXO:0000506 (oxygen therapy, verify).

Sources: MILES PMID:21410393; ATS/JRS 2016 PMID:27628078; PMC10713282; PMC6026235; clinicaltrials.gov NCT03253913, NCT01687179.

13. Prevention

Primary prevention: Not possible (genetic/somatic disease). Practical measures: avoid exogenous estrogen (estrogen-containing contraceptives/HRT) in known/at-risk patients; smoking cessation.
Secondary prevention / early detection: Surveillance of women with TSC for LAM (baseline HRCT, periodic PFTs) per TSC guidelines enables earlier detection. Consider LAM in any woman with spontaneous pneumothorax, unexplained dyspnea, chylous effusion, or renal AML — serum VEGF-D screening can identify cases non-invasively (PMC10327335, probability of LAM in women with spontaneous pneumothorax).
Tertiary prevention (complication avoidance): early/first-episode pleurodesis to prevent recurrent pneumothorax; AML embolization/surveillance to prevent hemorrhage; mTOR inhibition to slow functional decline; oxygen and rehab to limit disability; caution with air travel and counseling on pneumothorax symptoms.
Counseling: Genetic counseling for TSC-LAM families (autosomal-dominant TSC); reassurance that sporadic LAM is not heritable. Reproductive counseling regarding pregnancy-associated risk.
Immunization / public-health / environmental measures: standard respiratory vaccinations (influenza, pneumococcal, COVID-19); no infectious-disease or environmental prevention applies.

Sources: ATS/JRS guideline; PMC10327335; TSC surveillance consensus.

14. Other Species / Natural Disease

Taxonomy: Human disease — Homo sapiens (NCBITaxon:9606). Naturally occurring LAM is essentially human-specific.
Orthologous genes: Tsc1/Tsc2 are highly conserved — mouse Tsc2 (NCBI Gene 22084), rat Tsc2 (Gene 24855); the Eker rat carries a germline Tsc2 mutation (a spontaneous animal model of Tsc2 tumor predisposition).
Natural disease in animals: No well-recognized spontaneous LAM/PEComa epidemic in companion animals analogous to human LAM; the Eker rat develops Tsc2-driven uterine leiomyomas and renal tumors (the disease analog, not lung LAM per se). OMIA: TSC-related tumor predisposition in rat.
Comparative biology: The TSC–mTORC1 axis is deeply conserved (yeast TOR → mammalian mTOR), enabling cross-species mechanistic study; the female/estrogen dependence and lung tropism of human LAM are only partially recapitulated in models.
Zoonotic potential: None.

Sources: Eker-rat literature; OMIA; PMC4992946.

15. Model Organisms

Mouse models: - Uterine-specific Tsc2 knockout (conditional, e.g., Amhr2-Cre or progesterone-receptor-Cre driven): produces estrogen-dependent myometrial tumors with smooth-muscle and neural-crest features that spontaneously metastasize to lung* in ~50% of animals — the best genetic recapitulation of LAM's hormone dependence and lung tropism (PMC3753421; Molecular Endocrinology 2013). Strong support for the uterine-origin/metastasis hypothesis. - Tsc1/Tsc2 heterozygous mice develop renal and hepatic tumors (TSC-like) but do not faithfully reproduce pulmonary LAM* — a key limitation.

Rat model: - Eker rat (germline Tsc2 mutation) — source of the widely used ELT3 (Eker leiomyoma–derived) cell line, TSC2-null smooth-muscle cells expressing ERα/PgR.

Cell-line / xenograft models: - ELT3 cells and TSC2-null/patient-derived AML cells used in xenograft "pseudo-LAM" lung-metastasis assays. Estrogen strongly enhances pulmonary metastasis of ELT3 cells, via MEK1/2–ERK1/2 signaling, anoikis resistance (Bim suppression), and estradiol-driven neutrophil expansion (Discover Oncology 2014; PMC5111508; PMC10164661). - Patient-derived LAM cells / iPSC and 3D/organoid drug-screen systems — used for therapeutic screening (HDAC inhibitor lead, bioRxiv 2021).

Genetic-model types available: knockout (constitutive Tsc1/Tsc2 het), conditional/tissue-specific knockout (uterine Tsc2), spontaneous-mutant (Eker rat), and xenograft/induced metastasis models.

Phenotype recapitulation: Uterine-Tsc2-KO mouse captures hormone dependence, smooth-muscle/melanocytic marker profile, and spontaneous lung metastasis; ELT3 xenografts capture estrogen-driven metastasis and mTORC1 biology and respond to rapamycin. Limitations: no model fully reproduces human cystic lung destruction, the chronic indolent clinical course, or the exclusively female human epidemiology; lung "metastases" are myometrial-tumor deposits rather than authentic cyst-forming LAM lesions.

Applications: dissecting mTORC1 signaling, estrogen/ERα–mTOR crosstalk, anoikis/metastasis biology, and preclinical drug testing (rapamycin/everolimus, anti-estrogens, autophagy and HDAC inhibitors).

Resources/databases: MGI (mouse Tsc1/Tsc2), RGD (rat Tsc2, Eker), Cellosaurus (ELT3), ATCC; Alliance of Genome Resources.

Sources: PMC3753421; Discover Oncology 2014 (https://link.springer.com/article/10.1007/s12672-014-0192-z); PMC4992946; PMC5111508; PMC10164661; bioRxiv 2021.

Consolidated Key Citations (verify PMIDs before KB commit)

McCormack FX et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis (MILES). N Engl J Med 2011;364:1595-1606. PMID:21410393 (https://pubmed.ncbi.nlm.nih.gov/21410393/). Direct quote: "In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life."
McCormack FX et al. Official ATS/JRS Clinical Practice Guidelines: LAM Diagnosis and Management. Am J Respir Crit Care Med 2016;194(6):748-761. PMID:27628078 (https://pubmed.ncbi.nlm.nih.gov/27628078/).
Gupta N et al. 2017 ATS/JRS addendum (HRCT, transbronchial biopsy, pleural disease). PMC5694834.
Young L et al. Clinical utility of diagnostic guidelines and putative biomarkers in LAM (VEGF-D). Respir Res 2012;13:34. PMID:22513045 (https://pubmed.ncbi.nlm.nih.gov/22513045/).
Serum VEGF-D as diagnostic/therapeutic biomarker for LAM. PLOS One 2019 (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212776).
Carsillo T, Astrinidis A, Henske EP. Mutations in TSC2 and LOH in sporadic LAM. PNAS 2000. PMID:10737804 (verify).
Karbowniczek M et al. Recurrent LAM after transplantation: metastatic mechanism. Am J Respir Crit Care Med 2003 (https://www.atsjournals.org/doi/full/10.1164/rccm.200208-969OC).
Long-term clinical course and outcomes in LAM. Respir Res 2022. PMID:35717210 (https://pubmed.ncbi.nlm.nih.gov/35717210/).
Determinants of Progression and Mortality in LAM. Chest 2023 (https://www.sciencedirect.com/science/article/pii/S0012369223002726).
LAM clinical review. Breathe 2020;16:200007 (https://publications.ersnet.org/content/breathe/16/2/200007); PMC7714539.
Uterine-specific loss of Tsc2 → myometrial tumors in uterus and lungs. Mol Endocrinol 2013. PMC3753421.
Henske EP, McCormack FX. LAM — a wolf in sheep's clothing. J Clin Invest 2012 (https://www.jci.org/articles/view/58709).
OMIM #606690 (https://omim.org/entry/606690); MONDO:0011705 (https://monarchinitiative.org/MONDO:0011705); StatPearls NBK534231 (https://www.ncbi.nlm.nih.gov/books/NBK534231/).

Curator handoff note: This is the worktree branch add-lymphangioleiomyomatosis with an untracked kb/disorders/Lymphangioleiomyomatosis.yaml. The highest-value, well-anchored evidence items for the KB entry are: (1) MILES/sirolimus (PMID:21410393), (2) ATS/JRS guideline + VEGF-D 800 pg/mL threshold (PMID:27628078; PMID:22513045), (3) TSC2/mTORC1 LOH mechanism (PMID:10737804), (4) metastatic/recurrence-after-transplant model (Karbowniczek 2003), and (5) uterine-Tsc2-KO mouse model (PMC3753421). Before committing any of these as snippets, run just fetch-reference PMID:XXXX and verify each quote is an exact substring of the fetched abstract.